Is the business good?
How good a business is RYTM?
Rhythm Pharmaceuticals, Inc. keeps −84% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−84%
Operating margin · Biotechnology median −72% · 12 months to Q2 2026
- Share count, year on year
- +7.7%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 72%
R&D as % of revenue
- Gross margin
- 89%
Gross margin
| Year | Operating margin |
|---|---|
| FY2021 | −5392% |
| FY2022 | −758% |
| FY2023 | −238% |
| FY2024 | −204% |
| FY2025 | −101% |
Details›
- Gross margin12 months to Q2 2026
- 89%
- Operating margin12 months to Q2 2026
- −84%
- Net margin12 months to Q2 2026
- −86%
- R&D as % of revenue
- 72%
- Revenue, trailing twelve months
- $240M
- Net income, trailing twelve months
- −$205M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.